Guangzhou Cellprotek Pharmaceutical Co., Ltd., founded in April 2011 in the Science Park of Guangzhou, is a comprehensive biopharmaceutical company integrating new drug discovery, technology consulting and technology transfer. Up until now, our R&D team has been powered by many domestic and overseas experts and talents, including over 10 doctoral graduates, while above 60% of our research staff possesses a master degree. Cellprotek has formed a mature business and operation model, and implemented a standardized and systematic management system to back our R & D.
Cellprotek is committed to solving the unmet clinical needs of major acute and chronic neurodegenerative diseases, with innovative small molecule drugs. In addition, the company has launched development of healthcare products for the prevention of these diseases. Currently, there are 5 drug candidates in our R&D pipeline, and we have filed in more than 100 patent applications at home and abroad with over 60 being authorized, covering 48 countries or regions. Our R & D team has published over 20 academic articles, and received multiple honors and supports from different governmental projects, such as the National Science and Technology Major Project, the National Key Overseas Chinese Entrepreneurship Team, the Innovative R & D Organization of Guangdong Province and the Introduced Innovative Entrepreneurship Team of Guangdong Province.
Solve The Unmet Clinical Needs For The Treatment Of CNS Diseases.
Become a pioneer in the discovery of innovative small molecule drugs
Science Honesty Excellence Diligence Teamwork
Completion of the first funding round
In February, Androtriol (YC-6) injection Project was funded by the GETDD leading talent entrepreneurship project in science and technology;
In April, YC-6 injection received funding from the Leading Talent Entrepreneurship project in science and technology of Guangzhou;
In April, an IND (investigational new drug) application for YC-6 injection was submitted to National Food and Medical Products Administration.
In January, funded by the project of Innovative Entrepreneur Team introduced by Guangdong Province; and
In August, the core patent of YC-6 was authorized by US Patent and Trademark Office.
In January, YC-6 injection received phase 1 clinical trial approval;
In September, share-holding reform was completed and Cellprotek became a limited liability company; and
In September, phase I clinical trial of YC-6 injection initiated.
In January, Cellprotek was listed on the share transfer system of national middle and small-sized enterprises (SMEs);
In January, funded by the “13th Five-year National Major New Drug Development” project
In March, two projects received funding from Major Special Science and Technology Project (concerning people’s livelihood) from Industry-University-Research Cooperation in Guangzhou; and
In December, recognized as a new “High-tech Enterprise” of Guangdong.
In May, recognized as a corporate R & D organization of Guangzhou; and
In October, received the “National Key Overseas Chinese Team” title.
Phase I clinical trial of YC-6 injection were completed.
In July, Cellprotek received the phase II/III clinical trial approval for YC-6 injection.
In August, listed as the “Most Innovative Pharmaceutical Enterprises in Asian-Pacific Region (among SMEs)”, ranking 67th;
In October, obtained the certificate of Intellectual Property Management System Certification; and
In December, received the “New R & D Institutes of Guangdong Province” title.
Listed as one of the “Top-50 Innovative Bio-pharmaceutical Enterprises of Guangzhou (2019)”, ranking 39th.